Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

CYCC Relative to the S&P 500

CYCC Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Cyclacel Pharmaceuticals, Inc. (NASD:CYCC) seasonal charts above shows that a Buy Date of November 25 and a Sell Date of February 17 has resulted in a geometric average return of 1.54% above the benchmark rate of the S&P 500 Total Return Index over the past 19 years. This seasonal timeframe has shown positive results compared to the benchmark in 11 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 19 years by an average of 101.54% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

To download CYCC seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: CYCC